International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

LEARN MORE

The "Lists": What Do They Mean?

Author(s): Voliva John

Issue: Nov/Dec 2016 - Volume 20, Number 6
View All Articles in Issue

Page(s): 477-479

Download in electronic PDF format for $75

Abstract:

Related Keywords: John Voliva, RPh, U.S. Food and Drug Administration, FDA, International Academy of Compounding Pharmacists, IACP, do not compound, positive list, negative list, demonstrably difficult list, Pharmacy Compounding Advisory Committee, PCAC, Federal Food, Drug, and Cosmetic Act, FD&C Act, Section 503A, pharmacy regulation

Related Categories: LEGAL, SUPPORT, QUALITY CONTROL, DISCONTINUED FORMULATIONS, UNITED STATES PHARMACOPEIA CONVENTIONS, INFORMATION RESOURCES

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
The "Lists": What Do They Mean? Voliva John	Nov/Dec 2016 Pg. 477-479
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
Basics of Compounding: The "Negative" List Allen Loyd V	Jul/Aug 2015 Pg. 311-313
Basics of Compounding: The Revised "Not to Compound List" Allen Loyd V Jr	Jan/Feb 2015 Pg. 57-58
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G	May/Jun 2014 Pg. 208
The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List") Allen Loyd V Jr, Ashworth Lisa D	Jan/Feb 2005 Pg. 44-46
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Cabaleiro Joe	Sep/Oct 2021 Pg. 358-362
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Blankenship Cynthia E	Sep/Oct 2014 Pg. 379-380
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
IACP's Continuing Support of Compounding Pharmacists: Letter to the FDA Concerning 503B Outsourcing Facilities Miller David G	Mar/Apr 2014 Pg. 117-118
Legislative/Regulatory Update: From the International Academy of Compounding Pharmacists: Appropriations McCrory Gary	Mar/Apr 2016 Pg. 95-96
How to Develop and Maintain a Hazardous Drug List Dillon L Rad	May/Jun 2019 Pg. 182-186
International Academy of Compounding Pharmacists' Legislative Regulatory Update: Take Action! Stop the U.S. Good and Drug Administration's Misguided Veterminary Guidance Miller David G	Nov/Dec 2015 Pg. 449-450
The International Academy of Compounding Pharmacists Comments to the Draft Memorandum of Understanding Miller David G	Sep/Oct 2015 Pg. 375
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
The International Academy of Compounding Pharmacists Introduces a New President Rice Baylor	Mar/Apr 2017 Pg. 116-117
Return to Top